In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …

Importance Several studies were conducted to estimate the average incubation period of
COVID-19; however, the incubation period of COVID-19 caused by different SARS-CoV-2 …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …

Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2. Here, we examine the …

Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …